このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HA-Coated and Non-HA Threads for Midface Lifting and Nasolabial Fold Correction

2026年10月29日 更新者:Aptos, LLC.

Evaluation of Safety and Effectiveness of APTOS Threads - Absorbable Surgical Sutures Excellence Product Line Models for Mid-face Suspension by Mini-Invasive Surgery to Temporarily Fixate the Cheek Sub-dermis in a Repositioned Site for the Treatment of Moderate to Severe Nasolabial Fold.

This randomized study compared absorbable facial lifting threads with and without a hyaluronic acid (HA) coating in 144 adults with moderate-to-severe nasolabial folds, the lines extending from the sides of the nose toward the corners of the mouth. Participants were randomly assigned in a 1:1 ratio to receive either HA-coated or non-HA threads.

Follow-up continued for six months. The main assessments evaluated adverse events through Day 30 and changes in nasolabial fold severity at Day 90. Independent evaluators assessed standardized photographs, and participants rated their aesthetic improvement and satisfaction. Additional assessments examined safety and maintenance of improvement through Day 180

調査の概要

研究の種類

介入

入学 (実際)

144

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Batumi、グルジア、6000
        • "Total Charm Piazza",15 Vakhtang Gorgasali Street
      • Tbilisi、グルジア、0109
        • "Total Charm LTD", Orbeliani Str #18
      • Tbilisi、グルジア、0162
        • "Total Charm Vake", 87B Zakaria Paliashvili Street

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

22年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male and female subjects, 22+ years of age.
  2. Subjects who desire cheek lifting to correct age-related wrinkles in the mid-face as recommended by the treating investigator.
  3. Subject received a rating, in each cheek, by Investigator of at least Grade 3 or Grade 4 for wrinkling of the NLF in the mid-face according to the WSRS.
  4. If a woman is of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), then she must have a confirmed negative urine pregnancy test result at screening. If treatment is not provided at the screening visit, a negative urine pregnancy test result is required within 7 days before treatment.
  5. If a woman of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), subject confirms she will utilize at least one form of contraception throughout the duration of the study (6 months).
  6. Subjects who are able to understand the study requirements, including the obligation not to receive any other facial procedures or treatments affecting mid-face at any time during the study. These include procedures or treatments done at home or with a professional. Facial treatments include lasers, facial massages, and anything beyond common skincare routine.
  7. Subjects who are willing to participate in the study and to sign a witnessed/informed consent form.
  8. Subjects who are logistically able to present for all study visits and meet all study requirements.
  9. Subjects who are willing to complete a 30-day diary.
  10. Subjects who pass the pinprick and/or cotton swab facial nerve assessment

Exclusion Criteria:

  1. Abnormal rating in mid-face sensation, with inability to feel a 0.4 G monofilament or a cotton wisp at any site on the mid-face.
  2. Active acne or prominent acne scars in the treatment area.
  3. Active inflammatory or infectious conditions.
  4. Allergy or foreign body sensitivities to plastic biomaterials.
  5. Known bleeding disorder.
  6. Breast feeding, pregnant, or not on/willing to use contraception if of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile).
  7. Known collagen skin disorder.
  8. Pre-existing facial asymmetry.
  9. History of any device use on the mid-face in the prior 6 months (laser, Intense Pulsed Light [IPL], radiofrequency (RF), ultrasound, micro needling, micro needle RF, or cool based treatments).
  10. History of autoimmune or connective tissue disease.
  11. History of facelift, mid-face lift, lower facelift or neck lift that changes the facial structure and anchor points.
  12. History of fat transfer to the mid-face.
  13. History of injectable fillers other than temporary fillers such as HA or Radiesse to the mid-face at any time. Permanent and semi-permanent fillers are not allowed (Poly-L-lactic acids [PLLA], Sculptra).
  14. History of Kybella in the prior 6 months.
  15. History of facial trauma in the mid-face.
  16. History of facial surgical procedures.
  17. Inability to chew, puff cheek, or smile broadly.
  18. Metabolism irregularities.
  19. Receiving immunosuppressive therapy.
  20. Recent weight loss or intention to lose a significant amount of weight during the study period (2 body mass index [BMI] points).
  21. Subjects who have undergone cosmetic facial plastic surgery (with the exception of rhinoplasty or upper blepharoplasty) more than 2 years prior to enrollment, tissue grafting, or tissue lifting or augmentation with any permanent or semi-permanent filler.
  22. Subjects who have had temporary facial dermal filler injections below the orbital rim with HA-based fillers or Radiesse within 18 months, porcine-based collagen fillers within 24 months, or neuromodulator injections to the mid-face or lateral canthal lines, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months of entry in the study or who were planning to undergo any of these procedures at any time during the study.
  23. Subjects who have very thin skin in the mid-face region, who have a tendency to accumulate fluid in the lower eyelids, or who have large infraorbital fat pads (i.e., significant convexity or projection from the infraorbital fat pads).
  24. Subjects who have mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIVrelated disease.
  25. Subjects who are included to list of vulnerable populations (pediatric, pregnant, elderly individuals with visual or hearing impairments, mentally ill subjects).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:HA-Coated P(LA/CL) Lifting Threads

Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads coated with hyaluronic acid in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence HA, Visage Excellence Soft HA, or Nano Excellence HA threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation.

The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] and coated with non-animal-derived, non-cross-linked, medium-molecular-weight sodium hyaluronate. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence HA (190 mm), Visage Excellence Soft HA (100 mm), and Nano Excellence HA (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning.

実験的:Non-HA-Coated P(LA/CL) Lifting Threads

Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads without hyaluronic acid coating in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence, Visage Excellence Soft, or Nano Excellence threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation.

The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] without hyaluronic acid coating. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence (190 mm), Visage Excellence Soft (100 mm), and Nano Excellence (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Incidence of device and procedure related serious adverse events by Day 30 (Month 1) after the implantation procedure.
時間枠:From implantation through Day 30.
From implantation through Day 30.
Reduction in NLF severity at Day 90 (Month 3) after the implantation procedure in comparison with baseline grading, as assessed by blinded evaluators using the Wrinkles Severity Rating Scale (WSRS).
時間枠:Baseline and Day 90 after implantation
Baseline and Day 90 after implantation

二次結果の測定

結果測定
時間枠
Incidence of all adverse events after implantation of threads throughout the whole study.
時間枠:through Day 180 [Month 6] after the implantation procedure
through Day 180 [Month 6] after the implantation procedure
Incidence of early recovery symptoms related to the treatment (threads implantation) among adverse events reported by both patients and treating physician(s)
時間枠:Up to Day 14 after the implantation procedure.
Up to Day 14 after the implantation procedure.
Observed values and change from baseline in WSRS
時間枠:On Day 30 and Day 180.
On Day 30 and Day 180.
The proportion of subjects with improvement of ≥1 WSRS score at each visit
時間枠:Days 30, 90, and 180 after implantation.
Days 30, 90, and 180 after implantation.
Mean GAIS value assessed by blinded evaluators with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
時間枠:On Day 30, Day 90, and Day 180
On Day 30, Day 90, and Day 180
Mean GAIS value assessed by subject with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
時間枠:Days 30, 90, and 180 after implantation.
Days 30, 90, and 180 after implantation.
Patient satisfaction with the procedure outcome assessed using the mean total Face-QTM Satisfaction with Outcome score.
時間枠:At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Anna Kadzhaya, MD、Aptos LLC, Tbilisi, Georgia.15 Givi Amilakhvari Street

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年6月19日

一次修了 (実際)

2024年12月13日

研究の完了 (実際)

2025年3月1日

試験登録日

最初に提出

2026年10月29日

QC基準を満たした最初の提出物

2026年10月29日

最初の投稿 (実際)

2026年11月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する